On Tuesday March 23nd at 17:00 – 18:00 CET an Endo-ERN webinar about “Pituitary Gigantism: FIPA, AIP and XLAG” is organised. The Endo-ERN webinar will be held by Albert Beckers and Adrian F. Daly from Centre Hospitalier Universitaire de Liège.
Pituitary gigantism is a rare and severe disease caused by growth hormone secreting pituitary adenomas. Due to its onset in childhood and adolescence, pituitary gigantism, and its lifelong disease burden, pituitary gigantism is of relevance to both pediatric and adult endocrinologists. This webinar will present the important genetic advances that have been made in pituitary gigantism and will deal with the clinical challenges caused by specific forms such as FIPA-AIP mutations and X-linked acrogigantism (X-LAG).
The Endo-ERN newsletter of January 2021 is out now!
Read more about upcoming Endo-ERN webinars, Special supplemental issue on Rare Endocrine Conditions, EJP RD Research Training Workshops for ERN members and much more.
On Tuesday February 23rd at 17:00 CET an Endo-ERN CPMS webinar about “how to enroll a patient, start a panel and upload files to your panel” is organised.
Danielle Steenvoorden from our Operational Helpdesk will give you a live demonstration in CPMS Training Environment followed by a live Q&A.
If you have special requests for this demonstration, you can send an e-mail to cpmshelpdesk@endo.ern-net.eu
Within the EJP-RD project the 3rd Call for Research Training Workshops is now opened (27. January-7. March 2021).
Applicants from ERN Full Members or Affiliated Partners can submit WORKSHOP TOPICS on rare diseases research to obtain funds (25.000€) in order to conduct a 2-day workshop.
For more information you can visit the website.
On Tuesday March 2nd at 17:00 – 18:00 CET an Endo-ERN webinar about “Molecular diagnostic testing of imprinting disorders and related growth disturbances” is organised. The Endo-ERN webinar will be held by Prof Thomas Eggermann from University Hospital Aachen, Germany.
Molecular diagnostic testing imprinting disorders and related growth disorders is challenging due to the broad spectrum of molecular defects. Additionally, the decision on the molecular testing algorithm is hindered by the clinical heterogeneity of these entities. However, the precise identification of the nature of the defect is often a prerequisite for the clinical management and genetic counselling. With the development of molecular high-throughput assays (i.e. next generation sequencing), the knowledge on the contribution of genetic and epigenetic alterations to the etiology of inherited growth disorders has massively expanded. However, the rapid implementation of these new molecular tools in the diagnostic settings makes the interpretation of diagnostic data increasingly complex.
In this webinar, the different types of molecular alterations in patients with imprinting disorders and differential diagnosis will be reviewed, and genetic testing strategies will be explained. Based on own data it will be illustrated that comprehensive testing strategies have to be applied in diagnostic testing of congenital disorders.
The early diagnosis of a genetically based endocrine disorder contributes to a precise management and helps the patients and their families in their self-determined planning of life. Furthermore, the identification of a causative (epi)genetic alteration allows an accurate prognosis of recurrence risks for family planning as the basis of genetic counselling. Asymptomatic carriers of pathogenic variants can be identified, and prenatal testing might be offered, where appropriate.
The Endo-ERN newsletter of December 2020 is out now!
Read more about upcoming Endo-ERN webinars, Special supplemental issue on Rare Endocrine Conditions, EJP RD Research Training Workshops for ERN members and much more.
The WorldMEN meeting has something different compared to all the other classical meetings: it was first created to allow for intense discussions about the discovery of the genetic etiologies of tumor syndrome in 1984. Over the last years, the WorldMEN meetings expanded the scope of their participants to a wide audience of endocrinologists, surgeons, gastroenterologists, oncologists, geneticists and more, all concerned by the diagnosis and management not only of multiple endocrine neoplasia, endocrine tumor syndromes and the various diseases they include (Von Hippel Lindau disease, pheochromocytoma and paraganglioma, pituitary tumors, neuroendocrine tumors, neurofibromatosis, calcium disorders…), but also endocrine cancers in general. Still more than an update on these conditions with the world renown specialists who are at the cutting edge of research, the aim of this meeting is to allow for fruitful scientific discussions around multicentric studies and collaborative projects.
Accordingly, this 17th WorldMEN meeting was organized by inviting experts from all over the world to give you the most updated data on endocrine tumor syndromes during workshops that will leave a large time for discussions, or plenaries on genetics, diagnosis, consequences or treatments of such syndromes. Together with the input of the organizers of previous WorldMEN meetings, we have the support of both national (French Endocrine Society SFE, and the Endocrine Tumor Group GTE) and European Societies (European Neuroendocrine Association ENEA). Last but not least, new international guidelines on pheochromocytoma will be discussed, and updates on MEN1 guidelines will also be presented for the first time.
On Thursday January 28th at 17:00 – 17:30 CET an Endo-ERN CPMS webinar about “How to invite members to your panel, schedule a video meeting and join a video meeting” is organised.
Danielle Steenvoorden from the Operational Helpdesk will give you an overview of the following steps after opening a patient panel within CPMS: how invite members and schedule and join a video meeting. At the end of this webinar there will be a live Q&A for all your questions.
This is the second part of a series of webinars about CPMS.
The first webinar “CPMS: how to enroll a patient and start a panel” can be found on our website or live followed on the next planned date.
Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.
Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Rare Disease Day improves knowledge amongst the general public of rare diseases while encouraging researchers and decision makers to address the needs of those living with rare diseases.
In September 2020 the EJP RD launched its second call of the “European Reference Networks (ERNs) Training and support program” as part of the ‘Training and Empowerment’ activities that aim to fill the gap in education on rare diseases research.
The “Research Training Workshop” call is aimed at identifying workshop topics to train ERN researchers and clinicians in relevant innovative themes with a cross-ERN added value. Selected applicants will receive financial support for the organization of a 2-days workshop for 20 participants.
Training themes include innovative research methodologies, diagnostic research methodologies, interdisciplinary treatment approaches, such as gene therapy and transplantation, etc. Topics have been proposed by the ERNs or by investigators belonging to EJP RD beneficiary institutions.
The second round of submission and evaluation have been finalized in December 2020 and was coordinated by Alberto Pereira. As a result, four workshops were recommended for funding (listed below). The workshops will take place in the upcoming months.
- The 8th international conference on Ectodermal dysplasias (Smail Hadj-Rabia, INSERM, Dept of Dermatology, Paris, France)
- Trans-ERN Working Group for Spina Bifida Training: Workshop for future research on innovative diagnostic and interdisciplinary treatment (Giovanni Mosiello, Bambino Gesù Pediatric and Research Hospital, Rome, Italy)
- ERN multidisciplinary research workshop on diagnostics and treatment of high grade endometrial cancer (Cor de Kroon, LUMC, Dept of Gynaecology, Leiden, the Netherlands)
- Endocrine cancer – a challenge in adults and children (Barbara Jarzab, M. Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland)
The information on their launch and more details will be provided and updated on the EJP RD website.
